Clinical Trials Browser

Phase 2 × Withdrawn × HMPL-013 × Clear all

NCT05690035 2024-07-09

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Phase 2 Withdrawn

Lung Neoplasms